Cannabis has been legal for recreational adult use in Colorado and Washington since 2012, making those states more than a decade into an experiment that the rest of the world has been watching closely. With over 20 US states now having legal adult-use markets, enough data exists to begin drawing real conclusions about what legalisation does, and does not, do to public health outcomes.
Youth Use: The Most Politically Charged Question
One of the central arguments for keeping cannabis illegal was that legalisation would increase use among young people. The data from states with legal markets does not clearly support this prediction. Multiple analyses of national survey data (including the National Survey on Drug Use and Health and Monitoring the Future) have found that youth cannabis use rates have not significantly increased in states that legalised compared to states that did not, and in some analyses have actually shown modest declines in certain age groups following legalisation. This finding is counterintuitive but has held across multiple methodologically distinct research efforts. The proposed explanation is that regulated markets with age verification requirements actually create a more effective age barrier than informal black market supply chains, where dealers do not card customers. This does not mean youth use is not a concern, but it directly challenges the prediction that was made about legalisation’s effect on this specific outcome.
Traffic Safety: A Mixed and Contested Finding
Cannabis-impaired driving is the public health outcome where the evidence is most concerning. Multiple studies have found associations between cannabis legalisation and increased traffic fatalities in legal states, with some analyses suggesting a 5 to 8% increase in traffic fatalities in states following legalisation compared to control states. However, this research is contested. Confounding factors including concurrent changes in traffic patterns, other drug and alcohol use, distracted driving, and methodology differences between studies make causal attribution difficult. The absence of a reliable real-time impairment test for cannabis (discussed in our piece on THC and driving laws) means that enforcement responses to cannabis-impaired driving remain less effective than for alcohol, which is itself a structural challenge independent of whether cannabis is legal or not.
Overall Adult Use Rates
Adult cannabis use rates have increased in states with legal markets, and this is not a contested finding. Legal adult-use states show higher rates of current adult cannabis use than non-legal states, which is expected and to some degree the intended outcome of legalisation (shifting consumption from illegal to legal markets). What is less clear is how much of this increase represents genuinely new users rather than existing users simply being more willing to report use when it is legal, since legal status affects survey response honesty as much as it affects actual behaviour.
Mental Health: The Relationship Is Complex
The mental health impacts of cannabis legalisation represent one of the most actively studied and contested areas. Research has found associations between legal market access and increased cannabis use disorder treatment admissions, suggesting higher rates of cannabis dependence or problematic use in legal states. Studies have examined psychosis-related hospitalisations in legal states with mixed findings. Some research has found associations between more potent cannabis products available in legal markets and higher rates of cannabis-induced psychosis presentations, though this appears more related to product potency trends (high-THC concentrates) than to legalisation itself. On the positive side, some research has found reductions in alcohol use in legal cannabis states, with some users substituting cannabis for alcohol, which has its own health implications in both directions depending on which is the greater risk for a given individual.
The Black Market: Persisting Despite Legalisation
A consistent finding across legal states is that illegal cannabis markets have not been eliminated by legalisation. High tax rates, regulatory compliance costs, and the convenience and lower price of informal sources have maintained substantial illicit market activity alongside legal markets in most jurisdictions. California, which legalised in 2016, still has an estimated illicit market that rivals the legal market in size more than a decade later, according to state revenue and enforcement data. This has implications for the public health argument for legalisation (the regulated market’s safety advantages are not available to consumers who continue buying from unregulated sources) and has prompted policy debates about optimal tax rates and regulatory burden.
What the Evidence Suggests About Policy Approaches
Across these findings, a few consistent themes emerge for public health policy. Age verification in regulated markets appears to be at least as effective as prohibition at limiting youth access, and possibly more so. Traffic safety requires specific investment in impairment detection and enforcement rather than simply being resolved by legalisation. Product potency regulation (limits on THC concentration in consumer products) has become an important policy lever, with some states moving toward potency caps on concentrates. Tax and regulatory structures that maintain legal market competitiveness with the black market significantly affect how many consumers can access the safety benefits of the regulated supply chain.
Frequently Asked Questions
Has cannabis legalisation increased or decreased youth use?
Multiple large analyses of national survey data have found no significant increase in youth cannabis use in legal states compared to non-legal states, and some studies have found modest decreases in certain age groups. This contradicts the most commonly predicted outcome from legalisation opponents. The proposed mechanism is that age-verified regulated markets may be more effective at excluding minors than informal black market supply, where age verification does not occur. However, researchers note ongoing monitoring is essential given that legal markets are still relatively young and product variety continues to expand.
Has cannabis legalisation affected mental health outcomes?
The evidence is mixed and research is ongoing. Increased cannabis use disorder treatment rates in legal states suggest higher rates of problematic use. Some research has found associations with cannabis-induced psychosis presentations, though this appears more related to high-potency product trends than to legalisation per se. On the other side, some research has found reductions in alcohol use in legal cannabis states, with potential mental health implications in both directions. The honest summary is that the mental health impact is complex and context-dependent, not a simple positive or negative.
What happened to cannabis prices after legalisation?
Legal cannabis prices have generally declined over time in mature legal markets, driven by increased competition, improved cultivation efficiency, and regulatory adjustments. In Colorado, retail cannabis prices declined significantly in the years following legalisation, though legal prices still tend to exceed equivalent illicit market prices due to taxes and compliance costs, which is a central driver of the persistent illicit market. Some states with lower tax burdens have seen more competitive legal market pricing and faster illicit market displacement.
Has cannabis legalisation reduced opioid use or overdose rates?
Early research suggested a potential association between legal cannabis access and reduced opioid-related mortality, which attracted significant attention as a potential harm-reduction benefit of legalisation. More recent and methodologically sophisticated analyses have found more mixed results, with some studies finding the initially promising association diminishes or disappears after controlling for other variables. The opioid-cannabis substitution question remains actively researched and the current evidence is insufficient to make strong causal claims either way.
What does evidence from countries with different cannabis policies show?
The international comparison evidence is complicated by different regulatory models. The Netherlands has maintained a de facto legal market through coffeeshops for decades without full legalisation of cultivation, producing a dual market that does not map cleanly onto US-style full legalisation. Uruguay became the first country to fully nationalise cannabis sales in 2013, with highly regulated government-controlled distribution at low prices that has suppressed the illicit market effectively, though at the cost of limiting variety and availability. Canada’s national legalisation since 2018 has produced broadly similar findings to US states: adult use has increased, youth use has not significantly increased, illicit market persists, and traffic safety remains a concern requiring ongoing policy attention.
What is the biggest unresolved public health question about cannabis legalisation?
Among researchers, the relationship between legal access to high-potency cannabis products (particularly concentrates with 70 to 90% THC) and rates of cannabis use disorder and psychosis-related outcomes is probably the most important unresolved question. The research that initially evaluated legalisation effects mostly pre-dated the widespread availability of high-potency concentrates in legal markets. Understanding whether product potency regulation should accompany commercial legalisation, similar to how alcohol sales are limited to certain concentrations, is a central question for the next generation of cannabis policy design.
